Rockefeller Capital Management L.P. Has $145.80 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Rockefeller Capital Management L.P. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 452,590 shares of the medical research company’s stock after purchasing an additional 4,901 shares during the period. Rockefeller Capital Management L.P.’s holdings in Amgen were worth $145,800,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. LRI Investments LLC acquired a new position in Amgen in the 1st quarter worth $152,000. Cetera Investment Advisers lifted its position in shares of Amgen by 268.9% in the first quarter. Cetera Investment Advisers now owns 233,379 shares of the medical research company’s stock valued at $66,355,000 after buying an additional 170,108 shares during the last quarter. Cetera Advisors LLC boosted its position in Amgen by 151.3% during the first quarter. Cetera Advisors LLC now owns 70,984 shares of the medical research company’s stock worth $20,182,000 after purchasing an additional 42,739 shares during the period. Cetera Advisor Networks LLC boosted its holdings in shares of Amgen by 1.7% during the first quarter. Cetera Advisor Networks LLC now owns 111,213 shares of the medical research company’s stock worth $31,620,000 after acquiring an additional 1,842 shares during the period. Finally, Westwood Holdings Group Inc. increased its position in Amgen by 8.5% during the 1st quarter. Westwood Holdings Group Inc. now owns 86,987 shares of the medical research company’s stock worth $24,732,000 after buying an additional 6,798 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.0 %

Shares of AMGN stock opened at $280.07 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market cap of $150.55 billion, a P/E ratio of 35.86, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The business has a 50-day moving average price of $312.46 and a two-hundred day moving average price of $317.31. Amgen Inc. has a 12-month low of $257.80 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 19.52 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Leerink Partners cut their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Wolfe Research began coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Finally, TD Cowen raised their price objective on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $323.05.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.